Neprilysin Deficiency Protects Against Fat-Induced Insulin Secretory Dysfunction by Maintaining Calcium Influx

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.2337/db11-1593</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:12407011">http://nrs.harvard.edu/urn-3:HUL.InstRepos:12407011</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>


Neprilysin Deficiency Protects Against Fat-Induced Insulin Secretory Dysfunction by Maintaining Calcium Influx

Sakeneh Zraika,1 Duk-Su Koh,2 Breanne M. Barrow,1 Bao Lu,3 Steven E. Kahn,1 and Sofianos Andrikopoulos4

Neprilysin contributes to free fatty acid (FFA)-induced cellular dysfunction in nonislet tissues in type 2 diabetes. Here, we show for the first time that with prolonged FFA exposure, islet neprilysin is upregulated and this is associated with reduced insulin precursor mRNA and ATP levels, oxidative/nitratative stress, impaired potassium and calcium channel activities, and decreased glucose-stimulated insulin secretion (GSIS). Genetic ablation of neprilysin specifically protects against FFA-induced impairment of calcium influx and GSIS in vitro and in vivo but does not ameliorate other FFA-induced defects. Importantly, adenoviral overexpression of neprilysin in islets cultured without FFA reproduces the defects in both calcium influx and GSIS, suggesting that upregulation of neprilysin per se mediates insulin secretory dysfunction and that the mechanism for protection conferred by neprilysin deletion involves prevention of reduced calcium influx. Our findings highlight the critical nature of calcium signaling for normal insulin secretion and suggest that interventions to inhibit neprilysin may improve β-cell function in obese humans with type 2 diabetes. Diabetes 62:1593–1601, 2013

Fundamental to development of type 2 diabetes is failure of β-cells to secrete adequate amounts of insulin in order to maintain blood glucose levels within the normal range (1). A common feature of type 2 diabetes is obesity and concomitantly elevated free fatty acid (FFA) levels (2). It has long been recognized that elevated FFAs have differential effects on insulin secretion depending on duration of exposure; acute exposure leads to increased insulin secretion (3,4), while chronic exposure impairs insulin secretion and results in β-cell death (5,6).

Chronically elevated FFAs induce defects at multiple steps in the pathways governing insulin production and secretion. As palmitate is a predominant fatty acid in human plasma and is increased in obese individuals (7), its use in studies of β-cell function has relevance for human disease. Studies have shown that palmitate inhibits glucose-induced insulin promoter activity leading to suppression of insulin gene expression (8). Key enzymes in glucose and lipid metabolism are also dysregulated by palmitate exposure (9), leading to mitochondrial defects such as reduced ATP production (10) and induction of oxidative/nitratative stress (11,12). In addition, dysregulated calcium homeostasis (13,14) and soluble N-ethylmaleimide–sensitive factor attachment protein receptor (SNARE) complex assembly and/or expression (15,16) due to chronic FFAs have been reported. Thus, while numerous FFA-induced β-cell defects have been demonstrated, the critical cellular mediators that contribute to reduced insulin secretion remain incompletely defined.

Neprilysin is a widely expressed plasma membrane protein that in nonislet tissues (e.g., mesenteric fat, endothelium) is upregulated under conditions of elevated FFAs and has been postulated to mediate cellular dysfunction in type 2 diabetes (17–19). We recently demonstrated that neprilysin is synthesized in islets (20) and could therefore play a role in FFA-induced islet dysfunction. Its normal function depends on the tissue in which it is located, where it can exert effects via its dual activities: proteolysis (21) or protein binding (22–24). Typical functions comprise metabolism of various regulatory peptides of the nervous, cardiovascular, and immune systems (25). Functions relevant to the islet include involvement in various signaling pathways including the IGF receptor–Akt cell survival pathway (23,24,26), degradation of peptides like glucagon and glucagon-like peptide-1 (27), inhibition of islet amyloid formation (20,28), and being a component of the renin-angiotensin system (29,30). The contribution of islet neprilysin to insulin secretory (dys)function has not previously been investigated.

Given the central role of the islet in regulating glucose homeostasis and evidence that upregulation of neprilysin may be deleterious to cellular function, we sought to determine whether islet neprilysin contributes to FFA-induced insulin secretory dysfunction by studying the impact of neprilysin deficiency on insulin secretion after chronic exposure to palmitate in vitro and high-fat feeding in vivo.

RESEARCH DESIGN AND METHODS
Breeding pairs of neprilysin-deficient mice on a C57BL/6 background (C57BL/6.NEP−/−) were provided by Dr. B. Lu, Department of Pediatrics, Children’s Hospital, Harvard Medical School, Boston, Massachusetts (31), and a colony was established both in Seattle, Washington, for in vitro studies and in Melbourne, Australia, for in vivo studies. Age-matched C57BL/6J wild-type mice from The Jackson Laboratory were used as controls. For ensuring suitability of C57BL/6J mice as controls, C57BL/6.NEP−/− littermate mice were generated for confirmatory experiments. Studies were approved by the VA Puget Sound Health Care System Institutional Animal Care and Use Committee in Seattle and the Austin Health Animal Ethics Committee in Melbourne.

From the 1Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, Washington; the 2Department of Physiology and Biophysics, University of Washington, Seattle, Washington; the 3Department of Pediatrics, Children’s Hospital, Harvard Medical School, Boston, Massachusetts; and the 4Department of Medicine, Heidelberg Repatriation Hospital, University of Melbourne, Heidelberg Heights, Victoria, Australia.

Corresponding author: Sakeneh Zraika, zraikas@u.washington.edu.

Received 14 November 2012 and accepted 2 December 2012.

DOI: 10.2337/db11-1593

This article contains Supplementary Data online at http://diabetes.diabetesjournals.orglookup/suppl/doi:10.2337/db11-1593/-/DC1. © 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by -nc-nd/3.0/ for details.
Islet isolation and culture. Islets were isolated from 10-week-old female and male mice as previously described (32). After overnight recovery, islets were transferred to RPMI media containing 11.1 mmol/L glucose plus either 1 mmol/L glyburide or 500 μmol/L diazoxide. A methoxy-2-naphthylamine standard curve was used to determine neprilysin activity (Fig. 1A and protein (Fig. 1B) levels were unchanged, whereas neprilysin activity (Fig. 1C) was elevated 1.6-fold. Neprilysin deficiency provides selective protection against palmitate-induced reductions in glucose-stimulated insulin secretion. Insulin secretion under basal conditions (2.8 mmol/L glucose) and in response to glucose stimulation (20 mmol/L glucose) was assessed after 48-h culture of islets in the absence and presence of palmitate (Fig. 2A). In C57BL/6 islets, palmitate exposure increased basal and decreased glucose-stimulated insulin secretion (GSIS) as expected. In C57BL/6.NEP−/− islets, exposed to palmitate, basal insulin secretion was also increased. In contrast, GSIS was not decreased after chronic palmitate exposure in C57BL/6.NEP−/− islets. This same pattern of insulin secretion was also observed in cultured islets from C57BL/6.NEP+/+ and C57BL/6.NEP−/− littermates (Supplementary Fig. 1).

Islet insulin content (Fig. 2F) and pre-mRNA levels (Fig. 2C) were measured and found to be decreased after palmitate exposure in both C57BL/6 and C57BL/6.NEP−/− islets, indicating that protection conferred by neprilysin deficiency was not mediated by preventing palmitate-induced decreases in insulin biosynthesis but, rather, was selective for GSIS. Total protein content of islets from C57BL/6 and C57BL/6.NEP−/− islets, with 20 mmol/L glucose relative to 2.8 mmol/L glucose. In contrast, C57BL/6 islets exposed to palmitate had significantly reduced ATP levels with 20 mmol/L glucose. Similarly, C57BL/6.NEP−/− islets exposed to palmitate had reduced ATP levels with 20 mmol/L glucose.

Since FFA-induced oxidative/nitrative stress can adversely affect β-cell stimulus-secretion coupling (11,12), nitric oxide and nitrotyrosine (a marker for peroxynitrite) were measured in C57BL/6 and C57BL/6.NEP−/− islets cultured in the absence of palmitate, ATP levels increased with 20 mmol/L glucose relative to 2.8 mmol/L glucose. In contrast, C57BL/6 islets exposed to palmitate had significantly reduced ATP levels with 20 mmol/L glucose. Similarly, C57BL/6.NEP−/− islets exposed to palmitate had reduced ATP levels with 20 mmol/L glucose.

Neprilysin deficiency does not protect against palmitate-induced reductions in ATP levels or production of nitric oxide and peroxynitrite. For determination of the mechanism for protection against reduced GSIS in neprilysin-deficient islets, ATP levels were assessed after 48-h cultures (Fig. 3A). As expected in C57BL/6 and C57BL/6.NEP−/− islets, cultured in the absence of palmitate, ATP levels increased with 20 mmol/L glucose relative to 2.8 mmol/L glucose. In contrast, C57BL/6 islets exposed to palmitate had significantly reduced ATP levels with 20 mmol/L glucose. Similarly, C57BL/6.NEP−/− islets exposed to palmitate had reduced ATP levels with 20 mmol/L glucose.

Since FFA-induced oxidative/nitrative stress can adversely affect β-cell stimulus-secretion coupling (11,12), nitric oxide and nitrotyrosine (a marker for peroxynitrite) were measured in C57BL/6 and C57BL/6.NEP−/− islets cultured in the absence of palmitate, ATP levels increased with 20 mmol/L glucose relative to 2.8 mmol/L glucose. In contrast, C57BL/6 islets exposed to palmitate had significantly reduced ATP levels with 20 mmol/L glucose. Similarly, C57BL/6.NEP−/− islets exposed to palmitate had reduced ATP levels with 20 mmol/L glucose.

Neprilysin activity is upregulated with chronic palmitate exposure. We first determined whether islet neprilysin levels are increased with chronic FFA exposure as in other tissues (18,35). After 48-h culture of C57BL/6 mouse islets in the absence versus presence of palmitate, neprilysin mRNA (Fig. 1A) and protein (Fig. 1B) levels were unchanged, whereas neprilysin activity (Fig. 1C) was elevated 1.6-fold.

RESULTS
Neprilysin activity is upregulated with chronic palmitate exposure. We first determined whether islet neprilysin levels are increased with chronic FFA exposure as in other tissues (18,35). After 48-h culture of C57BL/6 mouse islets in the absence versus presence of palmitate, neprilysin mRNA (Fig. 1A) and protein (Fig. 1B) levels were unchanged, whereas neprilysin activity (Fig. 1C) was elevated 1.6-fold.
Calcium but not potassium channel activity is involved in protecting neprilysin-deficient islets from palmitate-induced insulin secretory dysfunction. As neprilysin has been suggested to modulate potassium and calcium ion flux in nonislet tissues (36,37), we investigated whether neprilysin may play a similar role in islets, thereby mediating palmitate-induced defects. Rubidium efflux, reflecting K+ permeability, decreased in response to 20 mmol/L glucose relative to 2.8 mmol/L glucose in both C57BL/6 and C57BL/6.NEPT−/− islets cultured in the absence of palmitate (Fig. 4). In the presence of palmitate, rubidium efflux in response to 20 mmol/L glucose was increased in C57BL/6 and C57BL/6.NEPT−/− islets compared with islets cultured in the absence of palmitate, suggesting that neprilysin’s site of action is likely distal to the potassium channel. Diazoxide, an opener, and glyburide, a blocker of KATP channels, were used as controls for increased and decreased rubidium efflux, respectively; no differences were observed between genotypes (diazoxide with 20 mmol/L glucose, C57BL/6 3.3 ± 0.4% 86Rb+/min vs. C57BL/6.NEPT−/− 2.8 ± 0.1% 86Rb+/min; glyburide with 2.8 mmol/L glucose, C57BL/6 1.9 ± 0.1% 86Rb+/min vs. C57BL/6.NEPT−/− 1.9 ± 0.1% 86Rb+/min; n = 5).

Influx of radiolabeled calcium (45Ca2+) into islet cells was increased in response to 20 mmol/L glucose relative to 2.8 mmol/L glucose in both C57BL/6 and C57BL/6.NEPT−/− islets cultured in the absence of palmitate (Fig. 5A). In C57BL/6 islets cultured in the presence of palmitate, calcium influx in response to 20 mmol/L glucose was decreased. In contrast, in C57BL/6.NEPT−/− islets cultured in the presence of palmitate, calcium influx in response to 20 mmol/L glucose remained unchanged compared with islets in the absence of palmitate. Nimodipine, an L-type calcium channel blocker, was used as a control in calcium influx studies. While nimodipine in the presence of 20 mmol/L glucose blocked calcium influx as expected, no difference was observed between genotypes (C57BL/6 3.6 ± 0.7 pmol/min vs. C57BL/6.NEPT−/− 4.0 ± 0.4 pmol/min; n = 5).

For confirmation that neprilysin deficiency was indeed protecting islets exposed to palmitate from reduced glucose-stimulated calcium influx, the more sensitive and real-time measure of calcium imaging using fluo-4 was used. Representative calcium imaging traces (Fig. 5B) clearly show that C57BL/6.NEPT−/− islets are protected from the effects of palmitate exposure to inhibit glucose-induced calcium influx. Mean data from fluo-4 experiments are expressed as the proportion of islet cells that responded (i.e., displayed enhanced fluorescence) to treatment with 20 mmol/L glucose (Fig. 5C). In C57BL/6 and C57BL/6.NEPT−/− islets cultured in the absence of palmitate, 37 and 41% of islet cells, respectively, responded to 20 mmol/L glucose. In contrast, in C57BL/6.NEPT−/− islets cultured in the presence of palmitate, only 13% of islet cells responded to 20 mmol/L glucose. In C57BL/6.NEPT−/− islets in the presence of palmitate, 31% of islet cells responded to
20 mmol/L glucose. Thus, the fluo-4 imaging data corroborate the "Ca" influx data, suggesting that neprilysin is involved in mediating FFA-induced insulin secretory dysfunction by inhibiting calcium influx.

**Upregulation of neprilysin in the absence of palmitate recapitulates the palmitate-induced impairment of GSIS.** Neprilysin was overexpressed in C57BL/6 islets to determine whether its upregulation is sufficient to inhibit calcium influx and reduce GSIS in the absence of palmitate. In AdV-NEP–infected islets, neprilysin protein and activity levels were increased 5.3 ± 1.8-fold and 4.5 ± 0.8-fold, respectively, versus control AdV-GFP–infected islets (n = 4–6, P < 0.05). Insulin secretion from both AdV-GFP– and AdV-NEP–infected islets was increased with 20 mmol/L glucose relative to 2.8 mmol/L glucose (Fig. 6A). However, in response to 20 mmol/L glucose, AdV-NEP–infected islets had significantly reduced insulin secretion compared with AdV-GFP–infected islets. Insulin content did not differ between AdV-GFP– and AdV-NEP–infected islets (Fig. 6B). Glucose-induced calcium influx was significantly reduced in AdV-NEP–infected versus AdV-GFP–infected islets (Fig. 6C).

**Neprilysin deficiency protects against high-fat diet–induced insulin secretory dysfunction in vivo.** High fat–fed C57BL/6 mice develop impaired GSIS in vivo (38,39). For determination of whether neprilysin deficiency can protect against FFA-induced secretory dysfunction in vivo, C57BL/6 and C57BL/6.NEP<sup>−/−</sup> mice were fed a low- or high-fat diet for 12 weeks, after which insulin secretion and sensitivity were assessed by IVGTT and IPITT, respectively. Body weights (data not shown) and islet morphology (Supplementary Fig. 2) did not differ after 12 weeks of feeding regardless of genotype or diet. At 8 weeks, plasma FFA levels were higher in mice fed a high-versus low-fat diet (1.25 ± 0.13 vs. 0.66 ± 0.07 mmol/L; n = 10 mice/group, P < 0.001). Despite the unexpected lack of weight gain, high-fat feeding had the expected effect of increasing fasting plasma glucose (Fig. 7A) and insulin (Fig. 7B) levels in both C57BL/6 and C57BL/6.NEP<sup>−/−</sup> mice. During the IVGTT, glucose levels were also elevated in mice fed a high-fat diet, with absolute levels at each time point being higher in C57BL/6.NEP<sup>−/−</sup> mice (Fig. 7C). However, glucose levels declined in parallel so that glucose tolerance, calculated as the glucose disappearance constant from 10 to 30 min, was comparable between high fat–fed C57BL/6 and C57BL/6.NEP<sup>−/−</sup> mice (high fat 0.016 ± 0.002 vs. 0.017 ± 0.001% per min; low fat 0.018 ± 0.001 vs. 0.022 ± 0.001% per min). The early insulin response (0–5 min) to glucose was reduced only in high fat–fed C57BL/6 mice (Fig. 7D). In contrast, the response in C57BL/6.NEP<sup>−/−</sup> mice.
fed a high-fat diet was increased and, when calculated in terms of the prevailing glucose level (Fig. 7D), remained unchanged compared with mice fed a low-fat diet. During the IPITT, glucose levels fell similarly in C57BL/6.NEP<sup>−−</sup> and C57BL/6 mice, though mice fed a low-fat diet were more insulin sensitive than mice fed a high-fat diet (Fig. 7E).

**DISCUSSION**

Chronic elevations in circulating FFAs often accompany type 2 diabetes (2), and prolonged FFA exposure contributes to β-cell dysfunction (5,6). Neprilysin is a novel islet protein linked to FFA-induced cellular dysfunction in other tissues in type 2 diabetes (17). Here, we show for the first time that with prolonged FFA exposure, islet neprilysin activity is upregulated and this is associated with β-cell dysfunction. In addition, adenovirus-mediated overexpression of neprilysin in islets is sufficient to impair GSIS without exposure to FFAs. Importantly, genetic ablation of neprilysin protects against FFA-induced impairment of GSIS by preventing reduced calcium influx. These data suggest an important role for neprilysin in mediating GSIS, specifically by regulating calcium flux.

In β-cells chronically exposed to elevated FFAs, multiple defects contribute to increased basal insulin secretion, reduced GSIS, and reduced insulin content (40). We now report that palmitate-induced perturbations are associated with increased neprilysin activity, a finding documented in other tissues (18,35). In neprilysin-deficient islets, however, palmitate exposure failed to impair GSIS, suggesting that increased neprilysin activity contributes to palmitate-induced
b-cell dysfunction. To definitively link increased neprilysin activity to decreased GSIS, we overexpressed neprilysin in C57BL/6 islets and assessed secretion after culture in the absence of palmitate. In line with the effect of palmitate to increase neprilysin activity and decrease GSIS, overexpression of neprilysin in the absence of palmitate reproduced the insulin secretion defect in response to glucose stimulation. Interestingly, overexpression of neprilysin did not alter basal insulin secretion or insulin content compared with islets infected with a control (AdV-GFP) adenovirus. This is in contrast to C57BL/6 islets cultured with palmitate, where basal insulin secretion was elevated and insulin content reduced compared with islets cultured without palmitate. With respect to this difference in basal insulin secretion, prolonged exposure to FFAs causes marked triglyceride deposition that at low glucose is associated with reduced malonyl-CoA content, an increased rate of fat oxidation (41), and thereby elevated insulin secretion. Such effects would not be expected in AdV-NEP-infected islets cultured without palmitate. When it is also considered that in neprilysin-deficient islets cultured with palmitate basal insulin secretion and insulin content were not normalized, collectively these findings indicate that increased neprilysin activity does not modulate basal insulin secretion or insulin content but, rather, specifically affects GSIS.

The mechanism by which neprilysin reduces GSIS after prolonged FFA exposure involves reduced calcium influx, since in neprilysin-deficient islets all defects except reduced calcium influx were observed with palmitate exposure, yet GSIS was not impaired. Further, AdV-NEP-infected islets cultured in the absence of palmitate showed defects in both calcium influx and GSIS. Calcium influx through voltage-gated calcium channels serves as a critical signal to trigger insulin exocytosis with calcium channel regulation requiring a number of accessory proteins. Neprilysin may play such a role to modulate calcium influx in b-cells. In fact, neprilysin has been shown to modulate calcium flux in lung

FIG. 5. Neprilysin-deficient islets exposed to palmitate are protected against reduced glucose-stimulated calcium influx. Calcium influx, measured using 45Ca2+ in response to 2.8 and 20 mmol/L glucose stimulation from C57BL/6 and C57BL/6.NEP−/− islets after 48-h culture in the absence or presence of 1 mmol/L palmitate (A) (n = 5). Representative traces for calcium imaging of islets loaded with fluo-4 and perifused with 2.8 mmol/L and 20 mmol/L glucose (B). Percentage of 20 mmol/L glucose–responsive cells per C57BL/6 or C57BL/6.NEP−/− islet after 48-h culture in the absence or presence of 1 mmol/L palmitate (C) (n = 11–14 islets/group), determined as increased fluo-4 emission intensity when the perifusion solution was switched from 2.8 to 20 mmol/L glucose. White bars, C57BL/6 islets; black bars, C57BL/6.NEP−/− islets. Data are means ± SEM. *P < 0.05 vs. control; †P < 0.05 vs. C57BL/6.
cells where recombinant neprilysin abolished, and neprilysin inhibition potentiated, calcium flux generated by neuropeptides (36). A similar role for neprilysin in β-cells would significantly impact insulin secretion. Further, the plasma membrane localization of neprilysin makes its potential interaction with calcium channels and/or accessory proteins that facilitate calcium influx plausible. Of note, neprilysin localization may explain why its ablation does not protect against FFA-induced reductions in insulin pre-

As neprilysin-deficient islets cultured with palmitate did not exhibit reduced glucose-mediated calcium influx despite reduced ATP levels, $K_{\text{ATP}}$ channel–independent mechanisms may be involved in maintaining GSIS. Perhaps the absence of neprilysin enables a key palmitate-derived mediator of $K_{\text{ATP}}$ channel–independent calcium action to facilitate calcium influx. It is noteworthy that compared with $K_{\text{ATP}}$ channel–dependent insulin secretion, the glucose dose response curve for $K_{\text{ATP}}$ channel–independent insulin secretion is left shifted (42), suggesting that the metabolic threshold (including ATP requirements) for secretion is lower. This would fit with the ability of neprilysin-deficient islets cultured with palmitate to secrete comparable levels of insulin upon glucose stimulation relative to C57BL/6 islets cultured without palmitate, despite lower ATP levels.

As neprilysin can exert effects via its dual activities—proteolysis (21) or protein binding (22–24)—it may possibly either cleave and/or directly bind the cellular component(s), or perhaps even calcium channel subunits, required for calcium influx. In support of a proteolytic role, neprilysin is known to cleave the α-subunit of Na,K-ATPase (37), the principal pump responsible for restoring equilibrium of Na$^+$ and K$^+$ ions across islet cell plasma membranes. A protein-binding role for islet neprilysin is supported by studies demonstrating that it directly binds proteins like PTEN (43) and the p110 subunit of phosphatidylinositol 3-kinase (23), which are involved in signaling pathways that alter hormone secretion (44,45) and modulate membrane ion channel activity (46,47). Whether neprilysin exerts a proteolytic or protein-binding function to mediate β-cell dysfunction will be the focus of future studies.

To evaluate the significance of our in vitro findings in an in vivo setting, we studied C57BL/6.NEP$^{-/-}$ and C57BL/6 mice after 12 weeks of high-fat feeding. Consistent with previous studies, C57BL/6 mice developed fasting hyperglycemia, fasting hyperinsulinemia, and impaired GSIS after a high-fat diet (38,39). C57BL/6.NEP$^{-/-}$ mice also developed fasting hyperglycemia and hyperinsulinemia but, in contrast, did not display reduced GSIS after a high-fat diet. This latter finding agrees with the in vitro data and strengthens the notion that neprilysin may be a critical mediator of fat-induced insulin secretory dysfunction. What remains in question, however, is why C57BL/6.NEP$^{-/-}$ mice exhibited fasting hyperglycemia despite no defect in GSIS. One potential explanation may be that since deletion of neprilysin in C57BL/6.NEP$^{-/-}$ mice is global, the absence of neprilysin in liver and peripheral tissues may be altering hepatic glucose production and/or peripheral insulin sensitivity, thereby impacting glycemia. That said, our IPITT data suggest that there is no effect of neprilysin deficiency on whole-body insulin action. While mice fed a high-fat diet were insulin resistant compared with mice fed a low-fat diet, insulin sensitivity did not differ between C57BL/6.NEP$^{-/-}$ and C57BL/6 mice. Mice fed a high-fat diet also had higher glucose levels during the IVGTT, but glucose disappearance (tolerance) was not affected by neprilysin deficiency. Our finding that neprilysin deficiency does not confer protection against all fat-induced metabolic defects is consistent with others in the literature (35,48). Importantly, it is not possible to ascertain whether other studies involving C57BL/6.NEP$^{-/-}$ mice also show protection against fat-induced reductions in GSIS, since only glucose but not insulin data are reported. Notwithstanding, our findings may be relevant for obese humans with type 2 diabetes. In fact, a human study showed that plasma neprilysin activity was positively correlated with BMI and measures of insulin resistance (35). Taken together with our findings, these data would suggest that inhibition of neprilysin under conditions of chronically elevated fat could be beneficial.

In summary, we demonstrate that islet neprilysin is upregulated under conditions of chronically elevated fat, which contributes to impaired GSIS. While neprilysin
Neprilysin-deficient mice are protected against high-fat diet-induced insulin secretory dysfunction. Fasting plasma glucose (A) and insulin (B) levels and plasma glucose (C) and insulin (D) levels in response to intravenous glucose and plasma glucose levels in response to intraperitoneal insulin (E) in C57BL/6 and C57BL/6.NEP−/− mice after 12 weeks on a low-fat (LF) or high-fat (HF) diet. The inset in D shows the early insulin response to intravenous glucose calculated as a ratio of the incremental areas under the insulin and glucose curves over the first 5 min. The inset in E shows the inverse area under the curve below baseline glucose after insulin administration. Closed circles, C57BL/6 LF; open circles, C57BL/6 high fat; closed squares, C57BL/6.NEP−/− low fat; open squares, C57BL/6.NEP−/− high fat. Data are means ± SEM; n = 14–18. *P < 0.05 vs. LF; ‡P < 0.05 vs. C57BL/6.

ACKNOWLEDGMENTS
This study was supported by National Institutes of Health (NIH) Grant DK-080945 (to S.Z.), the Department of Veterans Affairs, VA Puget Sound Health Care System, the Diabetes Australia Research Trust, and the National Health and Medical Research Council (NHMRC) of Australia. Calcium influx and rubidium efflux studies as well as histological studies were performed at the University of Washington’s Diabetes Research Center Cell Function Analysis Core and Cellular and Molecular Imaging Core, respectively, both of which are supported by NIH Grant DK-017047. S.A. was the recipient of a Career Development Award from the NHMRC of Australia.

No potential conflicts of interest relevant to this article were reported.

S.Z. conceived and designed the study, performed experiments, analyzed data, and wrote the manuscript. D.-S.K. performed experiments and edited the manuscript. B.M.B. performed experiments, analyzed data, and edited the manuscript. B.L. contributed the C57BL/6.NEP−/− mice. S.E.K. analyzed data and edited the manuscript. S.A. performed experiments, analyzed data, and edited the manuscript. S.Z. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

The authors thank P. Bergquist, C. Braddock, M. Cone, C. Forsyth, J. Langworthy, M. Peters, M. Watts, and J. Willard from the Seattle Institute for Biomedical and Clinical Research, and A. Blair and C. Rantzau from the University of Melbourne for excellent technical support.

REFERENCES
1. Kahn SE, Zraika S, Utzschneider KM, Hull RL. The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality. Diabetologia 2009;52:1003–1012
5. Sako Y, Grill VE. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology 1990;127:1580–1589
22. Gunji RK, Sipekort RG, Brenner DG, Slup MD. CD10 neutral endopeptidase 24.11 is phosphorylated by casein kinase II and coassociates with other phosphoproteins including the lyn src-related kinase. Blood 1998;98:4129–4135